Are there concerns about treatment with HMA/Venetoclax in a patient with extramedullary AML presenting with a large cardiac mass?

Is there a higher risk of rapid changes in cardiac mobility leading to arrest in a patient with cardiac involvement? Would single agent HMA first be more appropriate to minimize toxicity or is the efficacy trade-off unacceptable? The patient is elderly, minimally symptomatic but with worsening cytopenias and declining exercise tolerance.